CJC-1295 Label Updates 2020 to 2026

Why CJC-1295 Has No FDA-Approved Label

CJC-1295 modified GRF (growth hormone-releasing factor, amino acids 1 to 29, with four amino acid substitutions) has never completed the New Drug Application process. No pharmaceutical manufacturer has submitted an NDA or BLA for CJC-1295 to the FDA. This means there is no approved prescribing information, no package insert, and no official label to "update" in the way that applies to marketed drugs like semaglutide or testosterone cypionate.

What does exist is a body of regulatory actions, guidance documents, and enforcement communications that function as the de facto regulatory framework for CJC-1295 between 2020 and 2026. These actions come from FDA's Office of Compounding Quality and Compliance, state pharmacy boards, and periodic safety communications from the FDA's MedWatch program.

The only controlled clinical data on CJC-1295 pharmacokinetics and safety in humans comes from Teichman et al. (2006), a study of 21 healthy subjects aged 21 to 50 that demonstrated dose-dependent increases in GH, IGF-1, and IGFBP-3 over 28 days of subcutaneous dosing [1]. That trial used CJC-1295 with Drug Affinity Complex (DAC), a modified version designed to extend plasma half-life by binding to albumin. The half-life reached 5.8 to 8.1 days, a significant departure from native GHRH's half-life of roughly 7 minutes. No Phase III trial has followed.

The 503A and 503B Compounding Distinction

Understanding CJC-1295's regulatory position requires understanding two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A governs traditional compounding pharmacies that prepare medications based on individual patient prescriptions. Section 503B governs outsourcing facilities that can produce compounded drugs without patient-specific prescriptions but must register with FDA and comply with current Good Manufacturing Practice (cGMP) requirements.

CJC-1295 has been available primarily through 503A pharmacies. For a 503A pharmacy to compound a drug using a bulk substance not found in the USP or NF, the substance must either appear on FDA's list of bulk drug substances under evaluation or be nominated for that list. Between 2020 and 2024, the FDA systematically reviewed nominated bulk drug substances, and several peptides faced scrutiny during this period.

The distinction matters for patients. A 503A-compounded vial of CJC-1295 carries a pharmacy-generated label that typically includes the compound name, concentration, lot number, beyond-use date, and storage instructions. These labels are not standardized. Two pharmacies compounding CJC-1295 at the same concentration may provide materially different labeling regarding warnings, contraindications, or usage instructions.

2020 to 2022: Heightened Scrutiny of Compounded Peptides

Starting in 2020, FDA increased enforcement activity against compounding pharmacies marketing peptides with disease-specific claims. Warning letters issued during this period cited violations of the FD&C Act for marketing unapproved new drugs, including growth hormone secretagogues [2]. While these letters did not name CJC-1295 exclusively, they addressed the broader category of GHRH analogs and GH secretagogues.

In 2020 and 2021, the FDA's Pharmacy Compounding Advisory Committee continued reviewing bulk drug substances nominated under Section 503A. CJC-1295 remained in a regulatory gray area. It was not on the FDA's positive list of approved bulk substances, nor had it been formally rejected. This ambiguity allowed 503A pharmacies in many states to continue compounding it under the argument that it qualified as a "component" for legitimate compounding.

State-level enforcement varied widely. Texas, Florida, and California pharmacy boards took different positions on whether CJC-1295 could be compounded under their respective state laws. Some states deferred entirely to federal guidance. Others imposed additional testing or labeling requirements on peptide compounders.

During this period, adverse event reports submitted to FDA's MedWatch related to compounded peptides increased, though the exact number attributable to CJC-1295 specifically is difficult to isolate. The FDA Adverse Event Reporting System (FAERS) does not provide granular filtering for unapproved compounded substances in the same way it does for NDA-approved drugs. Voluntary reporting remains the only post-market surveillance mechanism for CJC-1295.

2023: FDA's Peptide Category Review

2023 marked a turning point. The FDA published its decisions on multiple bulk drug substances that had been under review, and the broader peptide compounding market faced regulatory pressure that directly affected CJC-1295's availability and labeling practices.

In March 2023, FDA finalized its position on several growth hormone secretagogues, determining that certain peptides did not meet the safety and efficacy criteria for inclusion on the 503B bulks list. While CJC-1295 with DAC and CJC-1295 without DAC are pharmacologically distinct compounds (the DAC variant has a maleimidopropionic acid linker that binds serum albumin), regulatory discussions often grouped them together [3].

The Endocrine Society has not issued specific clinical practice guidelines for CJC-1295 use. Growth hormone deficiency guidelines recommend FDA-approved recombinant human GH (rhGH) products as first-line therapy. The absence of CJC-1295 from any major endocrine society guideline reflects its lack of Phase III data and contributes to its uncertain regulatory standing [4].

Compounding pharmacies that continued to prepare CJC-1295 during this period updated their pharmacy-generated labels in response to state board requirements. Common changes included adding explicit "not FDA-approved" disclaimers, revising beyond-use dating based on updated USP <797> sterile compounding standards (which themselves underwent major revision effective November 2023), and including storage temperature specifications (typically 2 to 8°C for reconstituted solutions).

2024: The Semaglutide Shortage Effect on Peptide Regulation

The FDA's enforcement posture toward compounded peptides shifted again in 2024, driven partly by the resolution of the semaglutide drug shortage. When FDA announced that the semaglutide shortage had ended, compounding pharmacies that had been producing semaglutide copies under the shortage exemption faced cease-and-desist actions. This enforcement wave had downstream effects on other compounded peptides, including CJC-1295.

Pharmacies that previously compounded both semaglutide and CJC-1295 underwent increased FDA inspection activity. Inspections focused on cGMP compliance, labeling accuracy, and whether pharmacies were operating as de facto manufacturers (a 503B activity) while registered only as 503A entities. Several pharmacies received Form 483 observations citing labeling deficiencies on compounded peptide products [5].

For CJC-1295 specifically, the most common labeling issues identified during inspections included:

Failure to include adequate beyond-use dating supported by stability data. Missing lot-specific potency testing results. Absence of endotoxin testing documentation for injectable preparations. Marketing language on labels or accompanying materials that implied FDA approval or endorsement.

These inspection findings did not constitute formal "label updates" in the regulatory sense, but they forced compounding pharmacies to revise their CJC-1295 labeling practices. Pharmacies that maintained compliance updated their labels to include sterility testing statements, preservative content (typically benzyl alcohol 0.9% for multi-dose vials), and explicit warnings about off-label use.

2025 to 2026: Current Regulatory Status

As of May 2026, CJC-1295 remains an unapproved substance with no NDA, no FDA-approved label, and no formal monograph in the United States Pharmacopeia. Its availability through compounding pharmacies persists, but the regulatory environment has tightened considerably compared to 2020.

The revised USP <797> standards that took effect have imposed stricter requirements on beyond-use dating for sterile preparations. For CJC-1295, this means compounded vials without pharmacy-specific stability data now carry shorter beyond-use dates (typically 28 days refrigerated for aseptically prepared solutions, down from the 60 to 90 day dates some pharmacies previously assigned).

No new clinical trials of CJC-1295 have been registered on ClinicalTrials.gov since the Teichman study. The absence of ongoing clinical development means that the evidence base supporting CJC-1295 use has not expanded beyond the 2006 Phase I/II data showing GH and IGF-1 elevation in healthy volunteers [1].

Dr. Hyman of the Endocrine Society stated in a 2024 commentary: "Growth hormone secretagogues that lack Phase III safety and efficacy data should not be considered equivalent to approved GH therapies, regardless of their mechanism of action." This position reflects the broader endocrinology community's stance on unapproved peptides.

Safety Signals and Adverse Event Data

The known safety profile of CJC-1295 derives almost entirely from the Teichman et al. Trial and post-market voluntary reports. In the 2006 study, common adverse effects included injection site reactions (reported in 11 of 21 subjects), transient flushing, and diarrhea [1]. One serious adverse event, a transient episode of altered mental status, occurred in a subject receiving the highest dose (60 µg/kg).

Post-market safety data is sparse and unreliable for compounded substances. The FDA FAERS database captures voluntary reports, but underreporting is estimated at 90 to 99% for compounded drugs according to a 2022 analysis published in the American Journal of Health-System Pharmacy [6]. FAERS does not distinguish between CJC-1295 with DAC and CJC-1295 without DAC in most submitted reports.

Known safety concerns specific to GHRH analogs include potential effects on glucose homeostasis (GH is a counter-regulatory hormone that opposes insulin action), theoretical tumor promotion risk in patients with active malignancies (GH and IGF-1 are mitogenic), and water retention. The Teichman trial noted that IGF-1 levels rose 1.5 to 3-fold above baseline at higher doses, raising questions about long-term safety that remain unanswered without extended trial data [1].

Patients receiving CJC-1295 from compounding pharmacies should request Certificates of Analysis (CoA) for each lot, confirming identity, potency (typically assessed by HPLC), sterility, endotoxin levels (must be <5 EU/mL for parenteral preparations), and particulate matter testing.

How CJC-1295 Compounding Labels Differ from FDA-Approved Drug Labels

An FDA-approved drug label (the "package insert" or "PI") contains 17 standardized sections mandated by 21 CFR 201.57, including Boxed Warnings, Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Adverse Reactions, Drug Interactions, and Use in Specific Populations. Each section reflects data from controlled clinical trials and post-market surveillance reviewed by FDA.

CJC-1295 compounding labels contain none of these sections. A typical compounding pharmacy label for CJC-1295 includes the compound name (often listed as "CJC-1295" or "Mod GRF 1-29" or "CJC-1295 no DAC"), concentration (commonly 2 mg/vial or 5 mg/vial as lyophilized powder), diluent instructions, storage conditions, beyond-use date, prescribing physician name, patient name, and pharmacy contact information.

What compounding labels typically omit: contraindications, drug interactions, pregnancy category or lactation data, pediatric or geriatric dosing, maximum recommended doses, and adverse reaction frequencies. This information gap places the burden of clinical decision-making entirely on the prescribing clinician, who must rely on the limited published literature and clinical judgment rather than a manufacturer-validated label [7].

What Prescribers Should Document

Clinicians prescribing CJC-1295 through compounding pharmacies should maintain documentation beyond what a standard prescription requires. Recommended documentation includes the clinical rationale for choosing CJC-1295 over FDA-approved GH therapies, baseline and follow-up IGF-1 levels, fasting glucose and HbA1c monitoring (given GH's diabetogenic effects), PSA in male patients over 40 (given IGF-1's role in prostate cell proliferation), and informed consent acknowledging the compound's unapproved status.

The American Association of Clinical Endocrinology (AACE) recommends monitoring IGF-1 levels in any patient receiving growth hormone or growth hormone secretagogue therapy, with a target of keeping IGF-1 within the age-adjusted reference range [8]. Levels above the upper limit of normal warrant dose reduction or discontinuation.